Key facts
- This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 21 Aug 2024, 18:51.
Eric Karas - 19 Aug 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)
- Signature
- /s/ Kathleen Scott, Attorney-in-Fact
- Issuer symbol
- SPRY
- Transactions as of
- 19 Aug 2024
- Net transactions value
- -$125,000
- Form type
- 4
- Filing time
- 21 Aug 2024, 18:51:06 UTC
- Previous filing
- 04 Jan 2024
- Next filing
- 19 Sep 2024
- SEC
- View on sec.gov
Key filing fact
Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 21 Aug 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: -$125,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
SPRY
transaction
Common Stock
Options Exercise
- Transaction value
- $15,000
- Shares
- +10,000
- Change %
- +176%
- Price
- $1.50
- Shares after
- 15,693
- Date
- 19 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
SPRY
transaction
Common Stock
Sale
- Transaction value
- $140,000
- Shares
- -10,000
- Change %
- -64%
- Price
- $14.00
- Shares after
- 5,693
- Date
- 19 Aug 2024
- Ownership
- Direct
- Footnotes
- F2
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
SPRY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -1.6%
- Price
- $0.000000
- Shares after
- 604,588
- Date
- 19 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $1.50
- Footnotes
- F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Includes 1,984 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,232 shares acquired under the ESPP on December 29, 2023 and 2,477 shares acquired under the ESPP on June 28, 2024. |
| F2 | The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024. |
| F3 | Immediately exercisable. |